Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.56 |
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16491462 | 1.00 | PTK2 (0.56) | PTK2NCF1ELANEDNM1GPBAR1 | |
| SCHEMBL16491459 | 1.00 | PTK2 (0.56) | PTK2NCF1ELANEDNM1GPBAR1 | |
| SCHEMBL16491457 | 1.00 | PTK2 (0.56) | PTK2NCF1ELANEDNM1GPBAR1 | |
| SCHEMBL25488411 | 0.86 | NCF1 (0.56) | PTK2NCF1ELANEGPBAR1TLR8 | |
| SCHEMBL13701721 | 0.80 | NCF1 (0.60) | PTK2NCF1ELANEGPBAR1MEN1 | |
| SCHEMBL16491446 | 0.77 | CHRM2 (0.60) | PTK2DNM1MEN1KMT2ACYP1A2 | |
| SCHEMBL16491470 | 0.77 | CHRM2 (0.60) | PTK2DNM1MEN1KMT2ACYP1A2 | |
| SCHEMBL16491448 | 0.77 | CHRM2 (0.60) | PTK2DNM1MEN1KMT2ACYP1A2 | |
| SCHEMBL16491456 | 0.77 | CHRM2 (0.60) | PTK2DNM1MEN1KMT2ACYP1A2 | |
| SCHEMBL16491466 | 0.77 | CHRM2 (0.60) | PTK2DNM1MEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394253-B2 | Kinase protein binding inhibitors | HEALTH RESEARCH, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150051245-A1 | KINASE PROTEIN BINDING INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051245-A1 | KINASE PROTEIN BINDING INHIBITORS | PACSIN2, PRKCH, CKS1B | PTK2 84/4885NCF1 783/4885ELANE 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.